Savage M P, Goldberg S, Macdonald R G, Bass T A, Margolis J R, Whitworth H B, Taussig A S, Vetrovec G, Cowley M, Bove A A
Cardiac Catheterization Laboratory, Thomas Jefferson University Hospital, Philadelphia, PA 19107.
Am Heart J. 1991 Nov;122(5):1239-44. doi: 10.1016/0002-8703(91)90561-u.
Since platelet interactions appear to play an important role in the development of restenosis, attenuation of thromboxane-mediated reactions may improve the long-term outcome following coronary angioplasty. Phase II of the Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART) is a prospective, randomized, placebo-controlled study of thromboxane blockade in the prevention of restenosis following successful coronary angioplasty. Two forms of thromboxane blockade are evaluated: aspirin (a nonspecific inhibitor of thromboxane synthesis) and sulotroban (a specific thromboxane receptor antagonist). The design of this multicenter trial and the rationale for use of sulotroban in the prevention of restenosis are reviewed in this report.
由于血小板相互作用似乎在再狭窄的发生中起重要作用，减弱血栓素介导的反应可能会改善冠状动脉血管成形术后的长期预后。多医院东大西洋再狭窄试验（M-HEART）的II期是一项前瞻性、随机、安慰剂对照研究，旨在研究血栓素阻断在预防冠状动脉血管成形术成功后再狭窄中的作用。评估了两种形式的血栓素阻断：阿司匹林（一种非特异性血栓素合成抑制剂）和苏洛班（一种特异性血栓素受体拮抗剂）。本报告回顾了这项多中心试验的设计以及使用苏洛班预防再狭窄的理论依据。
